[Photo provided by Genexine]
When South Korea will be able to deliver news about a meaningful breakthrough in Covid-19 vaccine and cure is uncertain as they are still struggling with initial investigational stage.
Korean pharmaceutical companies rushed to join the global race to develop Covid-19 vaccines and treatments since the pandemic outbreak.
Several of them have progressed in their development, but no company has come forward with significant clinical data. Genexine is at the forefront in the Korean pharmaceutical industry with its shot candidate GX-19 under Phase 1 study.
Its trial results are expected to be released as soon as the end of this month, and any positive data will allow Genexine to enter Phase 2 trial sequentially as the company received IND approval for Phase 1 and 2a trials at the same time in June.
Other local peers are still waiting for a regulatory nod from the Ministry of Food and Drug Safety to conduct clinical trials.
GC Pharma is pushing ahead to develop a universal vaccine to prevent all types of coronavirus, including Covid-19.
By Kim Byung-ho and Minu Kim
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]